Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy.

ABSTRACT: Immunotherapy has significantly improved treatment outcomes in various cancer entities. To enhance immunogenicity and efficacy, and to further broaden its applicability, co-administration of anti-tumor vaccines is considered as a promising strategy. Here, we introduce adeno-associated virus (AAV) vectors, widely used for in vivo gene therapy, as a potent cancer vaccine platform. Our AAV vector-based vaccine combines antigen display on the capsid surface with a vector-mediated antigen overexpression targeting different components of the immune system in a unique chronological order by a single intramuscular application. Thereby, both profound and long-lasting antigen-specific T and B cell immune responses were induced. Moreover, mice receiving the vaccine were protected against tumor

SUBMITTER: Franke AC 

PROVIDER: S-EPMC10120303 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature